Signature d’un accord de fabrication sous contrat avec Yourgene Health Plc Accroissement de la capacité de production pour soutenir la demande du test COVID-19 de Novacyt

Paris, France et Camberley, Royaume-Uni – 25 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer suite à l’annonce du 20 mars 2020, que la société a signé un accord de fabrication sous contrat avec Yourgene Health Plc (“Yourgene”) (AIM : YGEN), un groupe

Visit Page

Global distribution agreement with Bruker for COVID-19 diagnostic test COVID-19 test receives FDA approval in the Philippines

Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker). http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update_Bruker-ENGLISH-25.03.20.pdf

Visit Page

Contract manufacturing services agreement signed with Yourgene Health Plc Additional manufacturing capacity to support demand for Novacyt’s COVID-19 diagnostic test

Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the notification on 20 March 2020, the Company has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (“Yourgene”) (AIM: YGEN), an international molecular diagnostics group.

Visit Page